Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Colchicine | Review

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

Authors: Praveen Dhyani, Cristina Quispe, Eshita Sharma, Amit Bahukhandi, Priyanka Sati, Dharam Chand Attri, Agnieszka Szopa, Javad Sharifi-Rad, Anca Oana Docea, Ileana Mardare, Daniela Calina, William C. Cho

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Cancer, one of the leading illnesses, accounts for about 10 million deaths worldwide. The treatment of cancer includes surgery, chemotherapy, radiation therapy, and drug therapy, along with others, which not only put a tremendous economic effect on patients but also develop drug resistance in patients with time. A significant number of cancer cases can be prevented/treated by implementing evidence-based preventive strategies. Plant-based drugs have evolved as promising preventive chemo options both in developing and developed nations. The secondary plant metabolites such as alkaloids have proven efficacy and acceptability for cancer treatment. Apropos, this review deals with a spectrum of promising alkaloids such as colchicine, vinblastine, vincristine, vindesine, vinorelbine, and vincamine within different domains of comprehensive information on these molecules such as their medical applications (contemporary/traditional), mechanism of antitumor action, and potential scale-up biotechnological studies on an in-vitro scale. The comprehensive information provided in the review will be a valuable resource to develop an effective, affordable, and cost effective cancer management program using these alkaloids.
Appendix
Available only for authorised users
Literature
1.
Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, Adetunji CO, Michael OS, Sytar O, Polito L, et al. Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev. 2021;2021:3687700.PubMedPubMedCentralCrossRef
2.
Sharifi-Rad J, Quispe C, Butnariu M, Rotariu LS, Sytar O, Sestito S, Rapposelli S, Akram M, Iqbal M, Krishna A, et al. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell Int. 2021;21(1):318.PubMedPubMedCentralCrossRef
3.
Mitrut P, Docea AO, Kamal AM, Mitrut R, Calina D, Gofita E, Padureanu V, Gruia C, Streba L. Colorectal cancer and inflammatory bowel disease. London: InTech; 2016.CrossRef
4.
Zlatian OM, Comanescu MV, Rosu AF, Rosu L, Cruce M, Gaman AE, Calina CD, Sfredel V. Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol. 2015;56(1):175–81.PubMed
5.
Buga AM, Docea AO, Albu C, Malin RD, Branisteanu DE, Ianosi G, Ianosi SL, Iordache A, Calina D. Molecular and cellular stratagem of brain metastases associated with melanoma. Oncol Lett. 2019;17(5):4170–5.PubMedPubMedCentral
6.
Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, et al. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis. 2019;36(4):305–9.PubMedPubMedCentralCrossRef
7.
Wild C, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention. Lyon: IARC Press; 2020.
8.
Sani TA, Mohammadpour E, Mohammadi A, Memariani T, Yazdi MV, Rezaee R, Calina D, Docea AO, Goumenou M, Etemad L, et al. Cytotoxic and apoptogenic properties of dracocephalum kotschyi aerial part different fractions on calu-6 and mehr-80 lung cancer cell lines. Farmacia. 2017;65(2):189–99.
9.
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022.
10.
Hossain R, Quispe C, Herrera-Bravo J, Islam MS, Sarkar C, Islam MT, Martorell M, Cruz-Martins N, Al-Harrasi A, Al-Rawahi A, et al. Lasia spinosa: chemical composition and therapeutic potential: a literature-based review. Oxid Med Cell Longev. 2021;2021:1602437.PubMedPubMedCentralCrossRef
11.
Astani A, Reichling J, Schnitzler P. Melissa officinalis extract inhibits attachment of herpes simplex virus in vitro. Chemotherapy. 2012;58(1):70–7.PubMedCrossRef
12.
Sharifi-Rad J, Quispe C, Bouyahya A, El Menyiy N, El Omari N, Shahinozzaman M, Ara Haque Ovey M, Koirala N, Panthi M, Ertani A, et al. Ethnobotany, phytochemistry, biological activities, and health-promoting effects of the genus Bulbophyllum. Evid Based Complement Altern Med. 2022;2022:6727609.CrossRef
13.
Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, Ahmad B, Atif M, Mubarak MS, Sytar O, et al. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid Med Cell Longev. 2021;2021:3268136.PubMedPubMedCentralCrossRef
14.
Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54(1):8–21.PubMedCrossRef
15.
Sharifi-Rad J, Dey A, Koirala N, Shaheen S, El Omari N, Salehi B, Goloshvili T, Cirone Silva NC, Bouyahya A, Vitalini S, et al. Cinnamomum species: bridging phytochemistry knowledge, pharmacological properties and toxicological safety for health benefits. Front Pharmacol. 2021;12:600139–600139.PubMedPubMedCentralCrossRef
16.
Sharifi-Rad J, Quispe C, Kumar M, Akram M, Amin M, Iqbal M, Koirala N, Sytar O, Kregiel D, Nicola S, et al. Hyssopus essential oil: an update of its phytochemistry, biological activities, and safety profile. Oxid Med Cell Longev. 2022;2022:8442734.PubMedPubMedCentralCrossRef
17.
Islam MT, Quispe C, El-Kersh DM, Shill MC, Bhardwaj K, Bhardwaj P, Sharifi-Rad J, Martorell M, Hossain R, Al-Harrasi A, et al. A literature-based update on Benincasa hispida (Thunb.) Cogn.: traditional uses, nutraceutical, and phytopharmacological profiles. Oxid Med Cell Longev. 2021;2021:6349041.PubMedPubMedCentralCrossRef
18.
Hossain R, Quispe C, Saikat ASM, Jain D, Habib A, Janmeda P, Islam MT, Radha, Daştan SD, Kumar M, et al. Biosynthesis of secondary metabolites based on the regulation of microRNAs. Biomed Res Int. 2022;2022:9349897.PubMedPubMedCentralCrossRef
19.
Salehi B, Sestito S, Rapposelli S, Peron G, Calina D, Sharifi-Rad M, Sharopov F, Martins N, Sharifi-Rad J. Epibatidine: a promising natural alkaloid in health. Biomolecules. 2019;9(1):6.CrossRef
20.
Salehi B, Sharifi-Rad J, Capanoglu E, Adrar N, Catalkaya G, Shaheen S, Jaffer M, Giri L, Suyal R, Jugran AK, et al. Cucurbita plants: from farm to industry. Appl Sci-Basel. 2019;9(16):21.
21.
Jain D, Chaudhary P, Varshney N, Bin Razzak KS, Verma D, Khan Zahra TR, Janmeda P, Sharifi-Rad J, Daştan SD, Mahmud S, et al. Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis. J Oncol. 2021;2021:5905357.PubMedPubMedCentralCrossRef
22.
Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M. Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine. EPMA J. 2020;11:261–87.PubMedPubMedCentralCrossRef
23.
Habli Z, Toumieh G, Fatfat M, Rahal ON, Gali-Muhtasib H. Emerging cytotoxic alkaloids in the battle against cancer: overview of molecular mechanisms. Molecules. 2017;22(2):250.PubMedCentralCrossRef
24.
25.
Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, Pezzuto JM, Viljoen A. Best practice in research—overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020;246:112230.PubMedCrossRef
26.
Ansari A, Saleem S, Kalam A. Management of Wajaʹ al-Rakba (knee Osteoarthritis) by TakmīdHārRatab (hot and moist fomentation) and Habb-i-Sūranjān: a case study. Int J AYUSH Case Rep. 2019;3(1):60–8.
27.
Borody TJ, Ramrakha S, Saxon J, Wettstein A. Gastric and colonic formulations and methods for making and using them. Google Patents; 2018.
28.
Ferreres F, Pereira DM, Valentão PC, Andrade PB, Seabra RM, Sottomayor M. New phenolic compounds and antioxidant potential of Catharanthus roseus. J Agric Food Chem. 2008;56(21):9967–74.PubMedCrossRef
29.
Barrales-Cureño HJ. Pharmacological applications and in vitro biotechnological production of anticancer alkaloids of Catharanthus roseus. Biotechnol Appl. 2015;32(1):1101–10.
30.
Kumar S, Singh B, Singh R. Catharanthus roseus (L.) G. Don: a review of its ethnobotany, phytochemistry, ethnopharmacology and toxicities. J Ethnopharmacol. 2021;284:114647.PubMedCrossRef
31.
Pham HNT, Vuong QV, Bowyer MC, Scarlett CJ. Phytochemicals derived from Catharanthus roseus and their health benefits. Technologies. 2020;8(4):80.CrossRef
32.
Afsahul KM, Anjum F. Suranjan (Colchicum autumnale L. and merendra persica): great resolvent herbs of Unani system of medicine-a review. Int J Unani Integr Med. 2020;4(1):7–11.
33.
34.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48(5):407–14.CrossRef
35.
Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89–97.PubMedCrossRef
36.
Robinson KP, Chan JJ. Colchicine in dermatology: a review. Australas J Dermatol. 2018;59(4):278–85.PubMedCrossRef
37.
Webb LJ. Guide to the medicinal and poisonous plants of Queensland. Bulletin of the Council for Scientific and Industrial Research, Australia. 1948(232).
38.
Bhandari P, Mukerji B. Lochnera rosea Linn Reichb. Gauhati Ayurvedic Coll Mag. 1959;8:1–4.
39.
Brandao M, Botelho M, Krettli E. Antimalarial experimental chemotherapy using natural products. I. A more rational approach? Ciência e Cultura. 1985;37(7):1152–63.
40.
Virmani O, Srivastava G, Singh P. Catharanthus roseus—the tropical periwinkle. Indian Drugs. 1978.
41.
Aslam J, Khan SH, Siddiqui ZH, Fatima Z, Maqsood M, Bhat MA, Nasim SA, Ilah A, Ahmad IZ, Khan SA. Catharanthus roseus (L.) G. Don. An important drug: it’s applications and production. Pharmacie Globale (IJCP). 2010;4(12):1–16.
42.
Nisar A, Mamat AS, Hatim MI, Aslam MS, Syarhabil M. An updated review on Catharanthus roseus: phytochemical and pharmacological analysis. Indian Res J Pharm Sci. 2016;3(2):631–53.
43.
Hsu FL, Cheng JT. Investigation in rats of the antihyperglycemic effect of plant extracts used in taiwan for the treatment of diabetes mellitus. Phytother Res. 1992;6(2):108–11.CrossRef
44.
Nguywen VD. List of simple drugs and medicinal plants of value in Vietnam. In: Proc seminar of the use of medicinal plants in healthcare Tokyo: 1977; 1977. pp. 13–17.
45.
Duflos A, Kruczynski A, Barret J-M. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem-Anti-Cancer Agents. 2002;2(1):55–70.CrossRef
46.
Gajalakshmi S, Vijayalakshmi S, Devi RV. Pharmacological activities of Catharanthus roseus: a perspective review. Int J Pharm Bio Sci. 2013;4(2):431–9.
47.
Meyers MA. Happy accidents: serendipity in modern medical breakthroughs. New York: Arcade Publishing; 2007.
48.
Farnsworth N. Plants and modern medicine: where science and folklore Meets. In: World Health Forum: 1985; 1985. pp. 76–80.
49.
Arora R, Malhotra P, Mathur AK, Mathur A, Govil C, Ahuja P. Anticancer alkaloids of Catharanthus roseus: transition from traditional to modern medicine. In: Arora R, editor. Herbal medicine: a cancer chemopreventive and therapeutic perspective. New Delhi: Jaypee Brothers Medical Publishers Pvt Ltd; 2010. p. 292–310.CrossRef
50.
Foye WO. Cancer chemotherapeutic agents. Washington: Amer Chemical Society; 1995.
51.
52.
Bennouna J, Delord J-P, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14(6):1625–32.PubMedCrossRef
53.
Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, Fan W, Dai R, Hu Z. Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts. Life Sci. 2004;74(20):2467–78.PubMedCrossRef
54.
Mishra JN, Verma NK. A brief study on Catharanthus roseus: a review. Intern J Res Pharm Pharm Sci. 2017;2(2):20–3.
55.
Sayeed M, Jesmin MH, Sarker T, Rahman M, Alam M. Antitumor activity of leaf extracts of Catharanthus roseus (L.) G. Don. 2014.
56.
Chattopadhyay R, Sarkar S, Ganguly S, Banerjee R, Basu T. Hypoglycemic and antihyperglycemic effect of leaves of Vinca rosea linn. Indian J Physiol Pharmacol. 1991;35(3):145–51.PubMed
57.
Chattopadhyay R. A comparative evaluation of some blood sugar lowering agents of plant origin. J Ethnopharmacol. 1999;67(3):367–72.PubMedCrossRef
58.
Patil PJ, Ghosh JS. Antimicrobial activity of Catharanthus roseus—a detailed study. Br J Pharmacol Toxicol. 2010;1(1):40–4.
59.
Bhutkar M, Bhise S. Studies on antioxidant properties of Catharanthus rosea and Catharanthus alba. J Curr Pharma Res. 2011;1(4):337.CrossRef
60.
Agarwal S, Jacob S, Chettri N, Bisoyi S, Tazeen A, Vedamurthy A, Krishna V, Hoskeri H. Evaluation of in-vitro anthelminthic activity of Catharanthus roseus extract. Int J Pharm Sci Drug Res. 2011;3(3):211–3.
61.
Rajput MS, Nair V, Chauhan A, Jawanjal H, Dange V. Evaluation of antidiarrheal activity of aerial parts of Vinca major in experimental animals. Middle-East J Sci Res. 2011;7(5):784–8.
62.
Hassan KA, Brenda AT, Patrick V, Patrick OE. In vivo antidiarrheal activity of the ethanolic leaf extract of Catharanthus roseus Linn. (Apocyanaceae) in Wistar rats. Afr J Pharm Pharmacol. 2011;5(15):1797–800.CrossRef
63.
Nayak B, Anderson M, Pereira LP. Evaluation of wound-healing potential of Catharanthus roseus leaf extract in rats. Fitoterapia. 2007;78(7–8):540–4.PubMedCrossRef
64.
Tiong SH, Looi CY, Hazni H, Arya A, Paydar M, Wong WF, Cheah S-C, Mustafa MR, Awang K. Antidiabetic and antioxidant properties of alkaloids from Catharanthus roseus (L.) G. Don. Molecules. 2013;18(8):9770–84.PubMedPubMedCentralCrossRef
65.
Patel Y, Vadgama V, Baxi S, Tripathi CB. Evaluation of hypolipidemic activity of leaf juice of Catharanthus roseus (Linn.) G. Donn. in guinea pigs. Acta Pol Pharm. 2011;68(6):927–35.PubMed
66.
Butnariu M, Quispe C, Herrera-Bravo J, Sharifi-Rad J, Singh L, Aborehab NM, Bouyahya A, Venditti A, Sen S, Acharya K, et al. The pharmacological activities of Crocus sativus L.: a review based on the mechanisms and therapeutic opportunities of its phytoconstituents. Oxid Med Cell Longev. 2022;2022:8214821.PubMedPubMedCentralCrossRef
67.
68.
Mandhare A, Banerjee P. Therapeutic use of colchicine and its derivatives: a patent review. Expert Opin Ther Pat. 2016;26(10):1157–74.PubMedCrossRef
69.
Kintz P, Jamey C, Tracqui A, Mangin P. Colchicine poisoning: report of a fatal case and presentation of an HPLC procedure for body fluid and tissue analyses. J Anal Toxicol. 1997;21(1):70–2.PubMedCrossRef
70.
Sussman JS, Brozena SC, Skop N, Korecka M, Shaw LM. Accidental intravenous colchicine poisoning. Ther Drug Monit. 2004;26(6):688–92.PubMedCrossRef
71.
Leung YY, Hui LLY, Kraus VB. Colchicine—update on mechanisms of action and therapeutic uses. In: Seminars in arthritis and rheumatism. Elsevier; 2015. pp. 341–50.
72.
Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, Liew D, Imazio M, Cornel JH, Thompson PL. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2021;135:32–8.PubMedPubMedCentralCrossRef
73.
Roubille F, Merlet N, Busseuil D, Ferron M, Shi Y, Mihalache-Avram T, Mecteau M, Brand G, Rivas D, Cossette M. Colchicine reduces atherosclerotic plaque vulnerability in rabbits. Atherosclerosis Plus. 2021;45:9.CrossRef
74.
Brvar M, Ploj T, Kozelj G, Mozina M, Noc M, Bunc M. Case report: fatal poisoning with Colchicum autumnale. Crit Care. 2004;8(1):1–4.CrossRef
75.
Noble RL, Beer C, Cutts J. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci. 1958;76(3):882–94.PubMedCrossRef
76.
Arora RD, Menezes RG. Vinca alkaloid toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
77.
Jordan M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem-Anti-Cancer Agents. 2002;2(1):1–17.CrossRef
78.
Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy. Arh Hig Rada Toksikol. 2019;70(3):160–72.PubMedCrossRef
79.
80.
Kurek J. Cytotoxic colchicine alkaloids: from plants to drugs. Cytotoxicity. 2018;6(45):10.5772.
81.
Ganguly A, Yang H, Zhang H, Cabral F, Patel KD. Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Mol Cancer Ther. 2013;12(12):2837–46.PubMedPubMedCentralCrossRef
82.
Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, Bhandary L, Martin SS. Curcumin targets breast cancer stem–like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. 2014;74(4):1250–60.PubMedCrossRef
83.
Cho JH, Joo YH, Shin EY, Park EJ, Kim MS. Anticancer effects of colchicine on hypopharyngeal cancer. Anticancer Res. 2017;37(11):6269–80.PubMed
84.
Chen X-M, Liu J, Wang T, Shang J. Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012;26(5):649–55.PubMedCrossRef
85.
Huang Z, Xu Y, Peng W. Colchicine induces apoptosis in HT-29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways. Mol Med Rep. 2015;12(4):5939–44.PubMedCrossRef
86.
Zhang T, Chen W, Jiang X, Liu L, Wei K, Du H, Wang H, Li J. Anticancer effects and underlying mechanism of Colchicine on human gastric cancer cell lines in vitro and in vivo. Biosci Rep. 2019;39(1):BSR20181802.PubMedPubMedCentralCrossRef
87.
Lin Z-Y, Kuo C-H, Wu D-C, Chuang W-L. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci. 2016;32(2):68–73.PubMedCrossRef
88.
Singh B, Kumar A, Joshi P, Guru SK, Kumar S, Wani ZA, Mahajan G, Hussain A, Qazi AK, Kumar A. Colchicine derivatives with potent anticancer activity and reduced P-glycoprotein induction liability. Org Biomol Chem. 2015;13(20):5674–89.PubMedCrossRef
89.
Bakar-Ateş F, Özmen N, Kaya-Sezginer E, Kurt EE. Effects of colchicine on cell cycle arrest and MMP-2 mRNA expression in MCF-7 breast adenocarcinoma cells. Turk Hij Den Biyol Derg. 2018;75:239–44.CrossRef
90.
91.
Taher ZM, Agouillal F, Marof AQ, Dailin DJ, Nurjayadi M, Razif EN, Gomaa SE, El Enshasy HA. Anticancer molecules from Catharanthus roseus. Indones J Pharm. 2019;30(3):147.CrossRef
92.
Allamsetty J, Pedada SP, Pedada N, Kolli D. A basic review on Vinca rosea. Int J Pharmacogn Chem. 2020:31–36.
93.
Retna AM, Ethalsa P. A review of the taxonomy, ethnobotany, chemistry and pharmacology of Catharanthus roseus (Apocyanaceae). Int J Eng Res Technol. 2013;2(10):3899–912.
94.
Tiong SH, Looi CY, Arya A, Wong WF, Hazni H, Mustafa MR, Awang K. Vindogentianine, a hypoglycemic alkaloid from Catharanthus roseus (L.) G. Don (Apocynaceae). Fitoterapia. 2015;102:182–8.PubMedCrossRef
95.
Almagro L, Fernández-Pérez F, Pedreño MA. Indole alkaloids from Catharanthus roseus: bioproduction and their effect on human health. Molecules. 2015;20(2):2973–3000.PubMedPubMedCentralCrossRef
96.
Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S. Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead. Bioorg Med Chem Lett. 2018;28(17):2816–26.PubMedCrossRef
97.
Pernot B, Gyan E, Maillot F, Hodges P, Ertault M, Ferreira-Maldent N. Lymphomas diagnosed in an internal medicine department compared to lymphomas diagnosed in other departments: clinical and outcome differences. Medicine. 2018;97(47):e13228.PubMedPubMedCentralCrossRef
98.
Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D. High-dose vincristine sulfate liposome injection, for advanced, relapsed, or refractory philadelphia chromosome-negative acute lymphoblastic leukemia in an adolescent and young adult subgroup of a phase 2 clinical trial. J Adolesc Young Adult Oncol. 2018;7(5):546–52.PubMedCrossRef
99.
Wang L, He H-P, Di Y-T, Zhang Y, Hao X-J. Catharoseumine, a new monoterpenoid indole alkaloid possessing a peroxy bridge from Catharanthus roseus. Tetrahedron Lett. 2012;53(13):1576–8.CrossRef
100.
Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8(8):2086–95.PubMedCrossRef
101.
Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, Plinkert PK, Krämer A, Gertsch J, Efferth T. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem Pharmacol. 2011;81(6):723–35.PubMedCrossRef
102.
Barbier P, Tsvetkov PO, Breuzard G, Devred F. Deciphering the molecular mechanisms of anti-tubulin plant derived drugs. Phytochem Rev. 2014;13(1):157–69.CrossRef
103.
Wang L, Liu X, Kreis W, Budman D. Activation of MAP kinase during apoptosis mediated by vinorelbine in MCF-7 cells. In: Proc Am Assoc Cancer Res; 1999. p. 13.
104.
Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102(3):401–16.PubMedCrossRef
105.
Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry. 1993;32(5):1285–93.PubMedCrossRef
106.
Vishwakarma R, Prajapati V. Drug of vinca: used as a anticancer agent. Int J Curr Res. 2019;1:40–4.
107.
Kumar A. Vincristine and vinblastine: a review. IJMPS. 2016;6:23–30.
108.
Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol. 2017;83(2):255–68.PubMedCrossRef
109.
Johnson IS, Armstrong JG, Gorman M, Burnett JP. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1963;23(8 Part 1):1390–427.PubMed
110.
Beck WT, Cass CE, Houghton PJ. Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes, and epothilones. In: Holland-Frei cancer medicine. 5th ed. BC Decker; 2000.
111.
112.
Joel S. The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Cancer Treat Rev. 1995;21(6):513–25.CrossRef
113.
114.
115.
Altinoz MA, Ozpinar A, Alturfan EE, Elmaci I. Vinorelbine’s anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas. J Chemother. 2018;30(4):203–12.PubMedCrossRef
116.
117.
Shao Y, Ding H, Tang W, Lou L, Hu L. Synthesis and structure–activity relationships study of novel anti-tumor carbamate anhydrovinblastine analogues. Bioorg Med Chem. 2007;15(15):5061–75.PubMedCrossRef
118.
Zhou X-J, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. 1992;44(4):1–16.PubMedCrossRef
119.
Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol. 2006;46(7):727–37.PubMedCrossRef
120.
Tiwari D, Tiwari M. Vincristine: Beyond on anticancer treatment. Int J Pharmacogn Life Sci. 2020;1:38–43.CrossRef
121.
Bairy K, Sanath S, Jagetia G, Somayaji S, Vidyasagar M, Baliga M. Evaluation of intraperitoneal vincristine in malignant peritoneal effusion. Indian J Physiol Pharmacol. 2003;47:270–8.PubMed
122.
Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, Nylandsted J, Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Can Res. 2007;67(5):2217–25.CrossRef
123.
Tu Y, Cheng S, Zhang S, Sun H, Xu Z. Vincristine induces cell cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells. Int J Mol Med. 2013;31(1):113–9.PubMedCrossRef
124.
Chao M-W, Lai M-J, Liou J-P, Chang Y-L, Wang J-C, Pan S-L, Teng C-M. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015;8(1):1–15.CrossRef
125.
Nielsen D, Dombernowsky P, Skovsgaard T, Jensen J, Andersen E, Engelholm S, Hansen M. Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Ann Oncol. 1990;1(4):275–80.PubMedCrossRef
126.
Smith I, Hedley D, Coombes R, Powles T. A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. Cancer Treat Rev. 1980;7:71–3.PubMedCrossRef
127.
Jewkes J, Harper P, Tobias J, Geddes D, Souhami R, Spiro S. Comparison of vincristine and vindesine in the treatment of inoperable non-small cell bronchial carcinoma. Cancer Treat Rep. 1983;67(12):1119–21.PubMed
128.
Cappellano AM, Petrilli AS, Da Silva NS, Silva FA, Paiva PM, Cavalheiro S, Bouffet E. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015;121(2):405–12.PubMedCrossRef
129.
Tuna S, Altinoz MA, Karasu A, Canbolat A, Bilir A. Selective COX-2 inhibitor (Rofecoxib) inhibits vinorelbine cytotoxicity in C6 glioma cells in vitro. Open Pathol J. 2009;3(1).
130.
Shi Y, Chen L, Li J, Lv Y-L, Sun Q, Wang L-X, Jiao S-C. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumor Biol. 2011;32(2):381–90.CrossRef
131.
Ameri A, Shahrad B, Fazlalizadeh A, Madani H, Mousavizadeh A, Moghadam S. Vinorelbine and docetaxel combination as the first line treatment in patients with metastatic breast cancer: results of a multi-centric phase ii trial in Iran. Rep Radiother Oncol. 2013;1(2):51–7.
132.
Khanavi M, Pourmoslemi S, Farahanikia B, Hadjiakhoondi A, Ostad SN. Cytotoxicity of Vinca minor. Pharm Biol. 2010;48(1):96–100.PubMedCrossRef
133.
Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G 1 and G 2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Investig. 2002;110(1):91–9.PubMedPubMedCentralCrossRef
134.
Al-Rashed S, Baker A, Ahmad SS, Syed A, Bahkali AH, Elgorban AM, Khan MS. Vincamine, a safe natural alkaloid, represents a novel anticancer agent. Bioorg Chem. 2021;107:104626.PubMedCrossRef
135.
Fleury C, Mignotte B, Vayssière J-L. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002;84(2–3):131–41.PubMedCrossRef
136.
Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10(3):218–27.PubMedCrossRef
137.
Pereira DM, Ferreres F, Oliveira J, Valentão P, Andrade PB, Sottomayor M. Targeted metabolite analysis of Catharanthus roseus and its biological potential. Food Chem Toxicol. 2009;47(6):1349–54.PubMedCrossRef
138.
Pereira DM, Ferreres F, Oliveira JM, Gaspar L, Faria J, Valentão P, Sottomayor M, Andrade PB. Pharmacological effects of Catharanthus roseus root alkaloids in acetylcholinesterase inhibition and cholinergic neurotransmission. Phytomedicine. 2010;17(8–9):646–52.PubMedCrossRef
139.
Quetglas-Llabrés MM, Quispe C, Herrera-Bravo J, Catarino MD, Pereira OR, Cardoso SM, Dua K, Chellappan DK, Pabreja K, Satija S, et al. Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev. 2022;2022:8615242.PubMedPubMedCentralCrossRef
140.
Taheri Y, Quispe C, Herrera-Bravo J, Sharifi-Rad J, Ezzat SM, Merghany RM, Shaheen S, Azmi L, Prakash Mishra A, Sener B, et al. Urtica dioica-derived phytochemicals for pharmacological and therapeutic applications. Evid Based Complement Altern Med. 2022;2022:4024331.CrossRef
141.
Salehi B, Capanoglu E, Adrar N, Catalkaya G, Shaheen S, Jaffer M, Giri L, Suyal R, Jugran AK, Calina D, et al. Cucurbits plants: a key emphasis to its pharmacological potential. Molecules. 2019;24(10):23.CrossRef
142.
Salehi B, Quispe C, Chamkhi I, El Omari N, Balahbib A, Sharifi-Rad J, Bouyahya A, Akram M, Iqbal M, Docea AO, et al. Pharmacological properties of chalcones: a review of preclinical including molecular mechanisms and clinical evidence. Front Pharmacol. 2021;11:592654.PubMedPubMedCentralCrossRef
143.
Docea AO, Mitrut P, Grigore D, Pirici D, Calina DC, Gofita E. Immunohistochemical expression of TGF beta (TGF-beta), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Rom J Morphol Embryol. 2012;53(3):683–92.PubMed
144.
Sutoo S, Maeda T, Suzuki A, Kato Y. Adaptation to chronic acidic extracellular pH elicits a sustained increase in lung cancer cell invasion and metastasis. Clin Exp Metastasis. 2020;37(1):133–44.PubMedCrossRef
145.
Sharifi-Rad J, Bahukhandi A, Dhyani P, Sati P, Capanoglu E, Docea AO, Al-Harrasi A, Dey A, Calina D. Therapeutic potential of neoechinulins and their derivatives: an overview of the molecular mechanisms behind pharmacological activities. Front Nutr. 2021;8:664197.PubMedPubMedCentralCrossRef
146.
Salehi B, Prakash Mishra A, Nigam M, Karazhan N, Shukla I, Kiełtyka-Dadasiewicz A, Sawicka B, Głowacka A, Abu-Darwish MS, Hussein Tarawneh A, et al. Ficus plants: state of the art from a phytochemical, pharmacological, and toxicological perspective. Phytother Res. 2021;35(3):1187–217.PubMedCrossRef
147.
Lin Z-Y, Yeh M-L, Huang C-I, Chen S-C, Huang C-F, Huang J-F, Dai C-Y, Yu M-L, Chuang W-L. Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. Kaohsiung J Med Sci. 2021;37(7):616–23.PubMedCrossRef
148.
Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA. Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity. Mol Pharm. 2014;11(4):1294–300.PubMedCrossRef
149.
Parthasarathy R, Shanmuganathan R, Pugazhendhi A. Vinblastine production by the endophytic fungus Curvularia verruculosa from the leaves of Catharanthus roseus and its in vitro cytotoxicity against HeLa cell line. Anal Biochem. 2020;593:113530.PubMedCrossRef
150.
Škubník J, Pavlíčková VS, Ruml T, Rimpelová S. Vincristine in combination therapy of cancer: emerging trends in clinics. Biology (Basel). 2021;10(9):849.
151.
Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555–64.PubMedCrossRef
152.
Kumar S, Singh B, Singh R. Catharanthus roseus (L.) G. Don: a review of its ethnobotany, phytochemistry, ethnopharmacology and toxicities. J Ethnopharmacol. 2022;284:114647.PubMedCrossRef
153.
Mhaidat NM, Alzoubi KH, Khabour OF, Alawneh KZ, Raffee LA, Alsatari ES, Hussein EI, Bani-Hani KE. Assessment of genotoxicity of vincristine, vinblastine and vinorelbine in human cultured lymphocytes: a comparative study. Balkan J Med Genet. 2016;19(1):13–20.PubMedPubMedCentralCrossRef
154.
Valerio MR, Spadaro P, Arcanà C, Borsellino N, Cipolla C, Vigneri P, Piazza D, Gebbia V. Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. Future Sci OA. 2021;7(10):Fso750.PubMedPubMedCentralCrossRef
155.
Lu J-J, Bao J-L, Chen X-P, Huang M, Wang Y-T. Alkaloids isolated from natural herbs as the anticancer agents. Evid-Based Complement Altern Med. 2012;2012:485042.CrossRef
156.
157.
Javarappa KK, Tsallos D, Heckman CA. A multiplexed screening assay to evaluate chemotherapy-induced myelosuppression using healthy peripheral blood and bone marrow. SLAS Discov. 2018;23(7):687–96.PubMedCrossRef
158.
Chagas CM, Alisaraie L. Metabolites of vinca alkaloid vinblastine: tubulin binding and activation of nausea-associated receptors. ACS Omega. 2019;4(6):9784–99.PubMedPubMedCentralCrossRef
159.
160.
Rubio-Gonzalez B, Juhász M, Fortman J, Mesinkovska NA. Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review. Int J Dermatol. 2018;57(12):1417–24.PubMedCrossRef
161.
Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Nurgali K, Abalo R. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol. 2022;13:750507.PubMedPubMedCentralCrossRef
162.
Khan AW, Farooq M, Haseeb M, Choi S. Role of plant-derived active constituents in cancer treatment and their mechanisms of action. Cells. 2022;11(8):1325.CrossRef
163.
Tvsvgk T, Handa A, Kumar K, Mutreja D, Subramanian S. Chemotherapy-associated pulmonary toxicity-case series from a single center. South Asian J Cancer. 2021;10(4):255–60.PubMedPubMedCentralCrossRef
164.
165.
166.
Haque A, Rahman MA, Faizi MSH, Khan MS. Next generation antineoplastic agents: a review on structurally modified vinblastine (VBL) analogues. Curr Med Chem. 2018;25(14):1650–62.PubMedCrossRef
167.
Docea AO, Calina D, Buga AM, Zlatian O, Paoliello MMB, Mogosanu GD, Streba CT, Popescu EL, Stoica AE, Birca AC, et al. The effect of silver nanoparticles on antioxidant/pro-oxidant balance in a murine model. Int J Mol Sci. 2020;21(4):17.CrossRef
Metadata
Title
Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine
Authors
Praveen Dhyani
Cristina Quispe
Eshita Sharma
Amit Bahukhandi
Priyanka Sati
Dharam Chand Attri
Agnieszka Szopa
Javad Sharifi-Rad
Anca Oana Docea
Ileana Mardare
Daniela Calina
William C. Cho
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02624-9

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Research

Extracellular matrix stiffness mediates radiosensitivity in a 3D nasopharyngeal carcinoma model

Primary research

DNA methyltransferase 1 inhibits microRNA-497 and elevates GPRC5A expression to promote chemotherapy resistance and metastasis in breast cancer

Review

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Review

A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities

Primary research

A pan-cancer analysis of molecular characteristics and oncogenic role of gasdermins

Primary research

Overexpression of CBS/H2S inhibits proliferation and metastasis of colon cancer cells through downregulation of CD44
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits